Marcin Cieślik

University of Michigan

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index54

i10-index99

Publications386

Citations23,296

Grants

1 total · 0 active

NIH #1R03OD032625-01

Unraveling the topological architecture and phenotypic contexture of structural variation

Amount: $297K
Period: 2021-09-22 → 2023-09-21
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF MICHIGAN AT ANN ARBOR

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 166

An immunocompetent Merkel cell carcinoma model for preclinical studies
bioRxiv (Cold Spring Harbor Laboratory) · 2026-06-26
Supplementary Table 1 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table 3 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table 4 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table 5 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table 2 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table 6 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
2026-06-18
Supplementary Table S2 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S2 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
2026-06-17
Supplementary Figure S9 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Figure S2 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Figure S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17
Supplementary Table S3 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
2026-06-17
Supplementary Table S1 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
2026-06-17
Supplementary Figure S7 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026-06-17

Open author page on OpenAlex →